Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials

Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut–liver axis in liver disease. We reviewed randomized controlled trials on gut...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ting-Rui, Yang, Wen-Juan, Tan, Qing-Hua, Bai, Shuai, Zhong, Huang, Tai, Yang, Tong, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884806/
https://www.ncbi.nlm.nih.gov/pubmed/36726574
http://dx.doi.org/10.3389/fmicb.2022.1004911
Descripción
Sumario:Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut–liver axis in liver disease. We reviewed randomized controlled trials on gut microbiota therapy in NAFLD in this study to evaluate its efficacy and plausibility in NAFLD.

Ejemplares similares